South and Central America Diltiazem Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Capsules, Injection, and Tablets) and Application (Angina, Hypertension, and Others)
Market Introduction
Diltiazem is a benzothiazepine derivative that acts as an antihypertensive and vasodilator. Diltiazem is an antihypertensive and vasodilator that lowers blood pressure by relaxing the vascular muscle. This is due to the long-term therapeutic effects of decreasing blood pressure since it lowers the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarction. According to in vitro binding experiments, diltiazem is 70%-80% bound to plasma proteins. At clinically relevant concentrations, around 40% of the medication is thought to attach to alpha-1-glycoprotein, whereas about 30% of the drug is thought to bind to albumin.
Get more information on this report :
Market Overview and Dynamics
The South and Central America diltiazem market is expected to reach US$ 57.03 million in 2028 from US$ 26.82 million in 2021; it is estimated to grow at a CAGR of 11.4% from 2021 to 2028. Rise in government initiatives for promotion, increase in the prevalence of cardiovascular diseases, and rise in the elderly population with heart diseases worldwide are expected to boost the market growth over the years. However, the side effects of Diltiazem on consumption are likely to impact the market's growth in the coming years negatively.
Diltiazem has potential use in a wide variety of cardiovascular disorders. According to the World Health Organization, cardiovascular diseases (CVDs) are the number one cause of death worldwide. CVDs are a major cause of morbidity and affect more people than any other disease. Tobacco consumption, unhealthy diet, and physical inactivity are major lifestyle factors that increase the risk of heart attacks and strokes. In addition, other risk factors that can lead to cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. The calcium channel blockers diltiazem (Cardizem) and verapamil (Calan and Apoptin) effectively control the initial ventricular rate in patients with atrial fibrillation. These agents are given intravenously in bolus doses until the ventricular rate becomes slower.
Furthermore, Diltiazem reduces conduction in the atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. Thus, the increasing prevalence of atrial fibrillation across the globe drives the diltiazem market. According to the Global Ageing 2019 survey, the world's population of 65 and above totaled 703 million in 2019. The elderly demographic is expected to double to 1.5 billion people by 2050. Also, the elderly population is more prompt to have atypical presentations, comorbid conditions, and unfavorable outcomes. Structural and functional changes in the cardiovascular system associated with aging are major causes of cardiovascular diseases. Therefore, the rising geriatric population worldwide is leading to an increase in the incidence of cardiovascular disease, bolstering the growth of the diltiazem market.
The COVID-19 outbreak has stringently affected medical services in South and Central America. The sudden outbreak of COVID-19 led to the implementation of stringent lockdown regulations across several nations, resulting in disruptions in import and export activities of Diltiazem. Also, the countries are famous for medical tourism, which is also influenced by the pandemic. It is anticipated that the region will likely force a second lockdown, which will ultimately hamper the healthcare industry in the area. There have been intensive attempts to explore drug therapy to prevent and treat SARS-CoV-2 infection during this COVID-19 pandemic. Thus, the ongoing clinical studies regarding Diltiazem for treatment in COVID-19 in the region are likely to favor the market's growth moderately.
Key Market Segments
Based on product, the South and Central America diltiazem market is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market. However, the capsules segment is expected to witness the fastest CAGR from 2021 to 2028.
Based on application, the South and Central America diltiazem market was segmented into angina, hypertension, and others. In 2021, the hypertension segment held the largest share of the market. The angina segment is expected to grow at the fastest CAGR during the coming years.
Major Sources and Companies Listed
A few of the primary and secondary sources associated with this report on the South and Central America diltiazem market are the Brazilian Institute of Geography and Statistics (IBGE), Argentine Society of Cardiology (SAC), and Centers for Disease Control and Prevention (CDC), among others.
Reasons to buy the report
- Determine prospective investment areas based on a detailed trend analysis of South and Central America diltiazem market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
- Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels driving the South and Central America diltiazem market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs undertaken by the different countries within the South and Central America diltiazem market.
SOUTH AND CENTRAL AMERICA DILTIAZEM MARKET SEGMENTATION
By Product Type
- Tablet
- Capsules
- Injection
By Application
- Hypertension
- Angina
- Others
By Country
- Brazil
- Argentina
- Rest of South and Central America
Company Profiles
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd
- MYLAN N.V.
- Pfizer Inc.
- Sandoz (Novartis AG)
- Sun Pharmaceutical Industries Ltd
- Hikma Pharmaceuticals PLC
- Zydus Cadila
- Glenmark
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 South and Central America Diltiazem Market – By Product Type
1.3.2 South and Central America Diltiazem Market – By Application
1.3.3 South and Central America Diltiazem Market – By Country
2. Diltiazem Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Diltiazem Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South and Central America (SCAM) – PEST Analysis
4.3 Experts Opinion
5. Diltiazem Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Cardiovascular Disease Incidence
5.1.2 Increasing Elderly Population
5.2 Market Restraints
5.2.1 Side Effects of Diltiazem
5.3 Market Opportunities
5.3.1 Growth Opportunities in Developing Nations
5.4 Future Trends
5.4.1 Recent Developments in Market
5.5 Impact Analysis
6. Diltiazem Market – South and Central America Analysis
6.1 South and Central America Diltiazem Market Revenue Forecast and Analysis
7. Diltiazem Market Analysis and Forecasts to 2028 – Product Type
7.1 Overview
7.2 Diltiazem Market Share by Product Type 2021 & 2028 (%)
7.3 Capsules
7.3.1 Overview
7.3.2 Capsules Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Injection
7.4.1 Overview
7.4.2 Injection Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Tablets
7.5.1 Overview
7.5.2 Tablet Market Revenue and Forecast to 2028 (US$ Mn)
8. Diltiazem Market Analysis and Forecasts TO 2028 – Application
8.1 Overview
8.2 Diltiazem Market Share by Application 2021 & 2028 (%)
8.3 Angina
8.3.1 Overview
8.3.2 Angina Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Hypertension
8.4.1 Overview
8.4.2 Hypertension Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Others
8.5.1 Overview
8.5.2 Others Market Revenue and Forecast to 2028 (US$ Mn)
9. Diltiazem Market – South and Central America Analysis
9.1 South and Central America: Diltiazem Market
9.1.1 Overview
9.1.2 South and Central America: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.3 South and Central America Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)
9.1.4 South and Central America Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
9.1.5 South and Central America: Diltiazem Market, by Country, 2021 & 2028 (%)
9.1.5.1 Brazil: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.5.1.1 Brazil: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.5.1.2 Brazil Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)
9.1.5.1.3 Brazil Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
9.1.5.2 Argentina: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.5.2.1 Argentina: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.5.2.2 Argentina Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)
9.1.5.2.3 Argentina Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
9.1.5.3 Rest of South and Central America: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.5.3.1 Rest of South and Central America: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.5.3.2 Rest of South and Central America Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)
9.1.5.3.3 Rest of South and Central America Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
10. Impact Of COVID-19 Pandemic on South and Central America Diltiazem Market
10.1 South and Central America: Impact Assessment of COVID-19 Pandemic
11. Diltiazem Market–Industry Landscape
11.1 Overview
11.2 Recent Growth Strategies in The Diltiazem Market
12. Company Profiles
12.1 Bausch Health Companies Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Teva Pharmaceutical Industries Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 MYLAN N.V.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Pfizer Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Sandoz (Novartis AG)
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Sun Pharmaceutical Industries Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Hikma Pharmaceuticals PLC
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Zydus Cadila
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Glenmark
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. South and Central America Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)
Table 2. South and Central America Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 3. Brazil Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)
Table 4. Brazil Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 5. Argentina Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)
Table 6. Argentina Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 7. Rest of South and Central America Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Rest of South and Central America Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 9. Glossary of Terms, Diltiazem Market
LIST OF FIGURES
Figure 1. Diltiazem Market Segmentation
Figure 2. Diltiazem Market Segmentation, By Country
Figure 3. Asia Pacific Diltiazem Market Overview
Figure 4. Tablets Held the Largest Share of the Product Segment in Diltiazem Market
Figure 5. South and Central America Diltiazem Market – Leading Country Markets (US$ Million)
Figure 6. South and Central America (SCAM) PEST Analysis
Figure 7. Diltiazem Market: Impact Analysis of Drivers and Restraints
Figure 8. South and Central America Diltiazem Market – Revenue Forecast and Analysis – 2020- 2028
Figure 9. Diltiazem Market Share by Product Type 2021 & 2028 (%)
Figure 10. Capsules Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Injection Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Tablet Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Diltiazem Market Share by Application 2021 & 2028 (%)
Figure 14. Angina Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 15. Hypertension Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Others Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. South and Central America: Diltiazem Market, by Key Country – Revenue (2021) (USD Million)
Figure 18. South and Central America Diltiazem Market Revenue and Forecast to 2028 (USD Million)
Figure 19. South and Central America: Diltiazem Market, by Country, 2021 & 2028 (%)
Figure 20. Brazil: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
Figure 21. Argentina: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
Figure 22. Rest of South and Central America: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
Figure 23. Impact Of COVID-19 Pandemic in South and Central America Africa Country Markets
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd
- MYLAN N.V.
- Pfizer Inc.
- Sandoz (Novartis AG)
- Sun Pharmaceutical Industries Ltd
- Hikma Pharmaceuticals PLC
- Zydus Cadila
- Glenmark
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South and Central America diltiazem market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South and Central America diltiazem market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.